Finland Pharmaceutical Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

Finland Pharmaceutical Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

The Finland Pharmaceutical Market is projected to register a CAGR of 3.9% during the forecast period.

According to the Finnish Medicines Agency, data updated in 2022, the COVID-19 pandemic in Finland did not significantly affect the availability of medications. To avoid complications even if the situation persists, Finnish healthcare and pharmaceutical operators were continually collaborating closely to prevent shortages. Companies evaluated the effects of the COVID-19 outbreak on production as well as the state of supply chains and stocks in collaboration with pharmaceutical producers and importers. Together with other companies in the industry, the authorities were closely observing the situation. For instance, the European medical authorities in Finland exchange updates on the issues faced within the country on a regular basis. In order to support the continued availability of medicines in the European Union (EU), the European Medicines Agency (EMA) supports the development and approval of safe and effective treatments and vaccines. It also supports the provision of accurate information to patients and healthcare professionals. In March 2021, Finnish academic– Rokote Laboratories Finland Ltd., worked on developing and marketing a nasal spray vaccine targeting COVID-19. The vaccine performed well in in-vivo studies with animal models. As a result of such developments, the market is expected to grow over the coming years.

According to the International Trade Administration, U.S. Department of Commerce, data updated in July 2022, Finland accounts for about 1.3% of European pharmaceutical sales and less than half a percent of global sales. In 2020, Finland imported USD 2.46 billion in pharmaceutical products and exported USD 978 million. In 2020, the Finnish population spent an estimated USD 4 billion on pharmaceutical products, which represented a 1% increase from the preceding year. The Finnish pharmaceutical industry consists of regulatory processes, routine checks, and safety testing for prescription drugs. Control and clarification are vital components of this policy's supervision. In Finland, the licenses for the production of pharmaceutical products and the wholesale license for pharmaceutical products are given by the Finnish Medicine Agency, Fimea. Under the Medicinal Products Act, only manufacturers of pharmaceutical products with appropriate manufacturing plants and equipment and a license granted by Fimea can manufacture pharmaceutical products industrially. The wholesale trade in pharmaceutical products is therefore subject to a license given by Fimea. According to Orion Corporation, data updated in October 2021, Finland’s recent growth has been impressive: investments in the pharmaceutical industry in Finland totaled EUR 330 million in 2020, which is 39% more than in the previous year.

As per an article titled "Well-functioning ecosystem for the pharmaceutical industry" published in 2021 by Pharma Industry Finland (PIF), exciting prospects and competitive advantages, particularly because of its highly qualified workforce and excellent university research, are expected to propel the market in the country. For instance, a long history of ground-breaking genetic research in Finland has established a strong foundation based on a trustworthy healthcare system and records, consistent medical procedures, high-quality public healthcare for the population, and a predictable business environment for investing. It is only through this strong foundation that growth can be achieved in the pharmaceutical sector.

As per the data published by the Pharmaceutical Industry Association, Finland in September 2022, the government is anticipated to boost research, development, and innovation (RDI) activities spending to 4% of GDP and keep working to strengthen RDI funding over the long term. By 2023, it is projected that central government funding for R&D will total EUR 2.4 billion. Pharmaceutical manufacturing spending in Finland increased by 80% in 2022 over the previous year, and companies in the field anticipate further growth of up to EUR 120 million in the near future. Moreover, in Finland, the pharmaceutical sector employs around 5,400 top professionals and specialists. Likewise, the entire amount invested in the pharmaceutical industry in 2021 was EUR 357 million. In 2021, production investments surged by 80% to a total of EUR 121 million.

The healthcare system in Finland has improved significantly in recent years with the advent of new technology and a substantial commitment from the government to create awareness regarding serious diseases and promote various services for the general population of the country. The health sector in Finland comprises a strongly regulated three-level public health network and a much smaller portion of the private sector. Whereas the Ministry of Social Affairs and Welfare has a very broad number of decision-making agencies, authorities, and local councils that are responsible for providing healthcare to their residents.

Thus, these aforementioned factors altogether are contributing to the market’s growth. However, highly expensive patented drugs are expected to hinder the market’s growth over the forecast period.

Key Market TrendsPrescription Drugs segment Holds the Largest Share and Expected to do Same in the Forecast Period

The prescription drugs segment is expected to garner a significant share of the market over the analysis period. Technical advances, a conducive governmental landscape, the preference of individuals for prescription drugs, and new product launches are also responsible for this positive trend. It would also be attributed to a rise in population growth and a surge in chronic diseases such as cardiovascular diseases, which are also the most common causes of death in the nation, along with a rise in per capita healthcare expenditure in the country and a change in people's disposable income that will drive growth during the forecast period.

According to Finnish Institute for Health and Welfare data updated in July 2022, public health concerns with a high mortality rate frequently include chronic diseases and disorders. The primary causes of premature death in Finland now are chronic diseases and accidents due to the fast drop in infectious disease mortality. Because of a dramatic decline in these infectious disease death rates over the past few decades, life expectancy has increased considerably. Cardiovascular illnesses, diabetes, asthma, allergies, chronic respiratory diseases, cancer, memory difficulties, musculoskeletal diseases, and mental disorders are among the chronic ailments and diseases that Finland considers to be significant public health challenges in recent years. The above-mentioned source also stated that the most common cardiovascular diseases include ischemic heart disease, congestive heart failure, and disorders of the cerebral circulation.

Similarly, as per an article titled "Long COVID could become Finland's largest chronic disease, warns minister" published in January 2022, more than 4,000 international studies found that one in two adults and around 2% of children may experience prolonged symptoms connected to COVID-19. Therefore, the increasing prevalence of chronic diseases in Finland is expected to drive the segment’s growth during the forecast period.

Competitive Landscape

The Finland pharmaceutical market is highly competitive and consists of several major players. In terms of market share, a few of the major players are currently dominating the market. And some prominent players are vigorously making acquisitions and joint ventures with other companies to consolidate their market positions in the country. Some of the key companies which are currently dominating the market are AbbVie Inc., AstraZeneca plc, Bayer AG, C.H. Boehringer Sohn AG & Ko. KG, and GlaxoSmithKline plc, among others.

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

Please note: This publisher does offer titles that are created upon receipt of order. If you are purchasing a PDF Email Delivery option above, the report will take approximately 2 business days to prepare and deliver.